Zargari 2006.

Methods	Design: randomized controlled trial Generation of allocation sequence: unclear Allocation concealment: "drugs ... packaged in identical appearing tubes and randomized and coded by the manufacturer" Blinding: participants and investigators Inclusion of randomized participants in the analysis: 84.6% (18/117 lost to follow up)
Participants	Number: 117 enrolled (aged 6 to 64 years, mean age 30.2 years +/‐ 15.3; 55 males and 44 females followed up) Inclusion criteria: clinically diagnosed scabies (defined as burrow or typical lesions at classical sites plus nocturnal pruritus plus similar symptoms in contacts) and/or microscopically diagnosed scabies (demonstration of egg, larvae, mite, or faecal material) Exclusion criteria: < 5 years of age; treatment with antiscabietic medication or topical steroid in previous 4 weeks; pregnancy; breastfeeding; severe central nervous system, hepatic, or renal problems
Interventions	1. 5% permethrin cream (59 participants) 2. 1% lindane cream (58 participants) Both medications applied as a single application head to toe, and repeated 1 week later
Outcomes	1. Number of participants with no new lesions and improvement in itching at 14 days 2. Adverse events
Notes	Location: Iran Date: December 2002 to October 2003 Treatment advised for all family members and close contacts Study supported by Gilaranco Company (manufacturers of permethrin and lindane)